A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

ClinicalTrials.gov ID: NCT02275351

Public ClinicalTrials.gov record NCT02275351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).

Study identification

NCT ID: NCT02275351
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Enrollment: 302 participants

Conditions and interventions

Conditions

Androgenetic Alopecia

Interventions

Topical SM04554 solution Drug
Topical vehicle solution Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2014 (Actual)
Primary completion: Nov 2015 (Actual)
Completion: Nov 2015 (Actual)
Last update posted: Oct 21, 2026

2014 – 2015

United States locations

U.S. sites: 24
U.S. states: 15
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Encinitas	California	92024	—
Not listed	San Diego	California	92123	—
Not listed	New Haven	Connecticut	06511	—
Not listed	Miami	Florida	33143	—
Not listed	West Palm Beach	Florida	33401	—
Not listed	Plainfield	Indiana	—	—
Not listed	Wichita	Kansas	67207	—
Not listed	Clinton Township	Michigan	48038	—
Not listed	Detroit	Michigan	48202	—
Not listed	Fridley	Minnesota	55432	—
Not listed	Albuquerque	New Mexico	87106	—
Not listed	New York	New York	—	—
Not listed	Stony Brook	New York	11790	—
Not listed	Winston-Salem	North Carolina	27104	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Portland	Oregon	97210	—
Not listed	Portland	Oregon	97223	—
Not listed	Austin	Texas	78759	—
Not listed	College Station	Texas	77845	—
Not listed	Dallas	Texas	75246	—
Not listed	Houston	Texas	—	—
Not listed	Salt Lake City	Utah	84117	—
Not listed	Lynchburg	Virginia	24501	—
Not listed	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02275351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 21, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02275351 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →